A FGFR1 inhibitor patent review: progress since 2010

References

• Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34:280–300.
   PubMed Web of Science ®Google Scholar
• Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7:165–197.
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235–253.
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–149.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–129.
   PubMed Web of Science ®Google Scholar
• Itoh N, Terachi T, Ohta M, et al. The complete amino acid sequence of the shorter form of human basic fibroblast growth factor receptor deduced from its cDNA. Biochem Biophys Res Commun. 1990;169:680–685.
   PubMed Web of Science ®Google Scholar
• Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993;60:1–41.
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2:62ra93.
   PubMed Web of Science ®Google Scholar
• Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997;57:4360–4367.
   PubMed Web of Science ®Google Scholar
• Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673–684.
   PubMed Web of Science ®Google Scholar
• Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41:461–476.
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105:8713–8717.
   PubMed Web of Science ®Google Scholar
• Hernández S, López-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24:3664–3671.
   PubMed Web of Science ®Google Scholar
• Taylor J, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009;119:3395–3407.
   PubMed Web of Science ®Google Scholar
• Wu J, Wei T, Tang Q, et al. Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer. BMC Cancer. 2015;15:276.
   PubMed Web of Science ®Google Scholar
• Irschick R, Trost T, Karp G, et al. Sorting of the FGF receptor 1 in a human glioma cell line. Histochem Cell Biol. 2013;139:135–148.
   PubMed Web of Science ®Google Scholar
• Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085–2094.
   PubMed Web of Science ®Google Scholar
• Yang F, Zhang Y, Ressler SJ, et al. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013;73:3716–3724.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo KJ, Shang H, et al. Expression of aFGF, bFGF, and FGFR1 in ovarian epithelial neoplasm. Chin Med J (Engl). 2004;117:601–603.
   PubMed Web of Science ®Google Scholar
• Bruno IG, Jin W, Cote GJ. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet. 2004;13:2409–2420.
   PubMed Web of Science ®Google Scholar
• Xu W, Xie Y, Wang Q, et al. A novel fibroblast growth factor receptor 1 inhibitor protects against cartilage degradation in a murine model of osteoarthritis. Sci Rep. 2016;6:24042.
   PubMed Web of Science ®Google Scholar
• Cilvik SN, Wang JI, Lavine KJ, et al. Fibroblast growth factor receptor 1 signaling in adult cardiomyocytes increases contractility and results in a hypertrophic cardiomyopathy. PLoS One. 2013;8:e82979.
   PubMed Web of Science ®Google Scholar
• Mazen I, Amin H, Kamel A, et al. Homozygous mutation of the FGFR1 gene associated with congenital heart disease and 46,XY disorder of sex development. Sex Dev. 2016;10:16–22.
   PubMed Web of Science ®Google Scholar
• Chen P-Y, Friesel R. FGFR1 forms an FRS2-dependent complex with mTOR to regulate smooth muscle marker gene expression. Biochem Biophys Res Commun. 2009;382:424–429.
   PubMed Web of Science ®Google Scholar
• Kucinski A, Wersinger S, Stachowiak EK, et al. Neuronal nicotinic receptor agonists ameliorate spontaneous motor asymmetries and motor discoordination in a unilateral mouse model of Parkinson’s disease. Pharmacol Biochem Behav. 2013;111:1–10.
   PubMed Web of Science ®Google Scholar
• Galitzer H, Ben-Dov IZ, Silver J, et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77:211–218.
   PubMed Web of Science ®Google Scholar
• Krajisnik T, Olauson H, Mirza MA, et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int. 2010;78:1024–1032.
   PubMed Web of Science ®Google Scholar
• Drüeke TB. Klotho, FGF23, and FGF receptors in chronic kidney disease: a yin-yang situation?. Kidney Int. 2010;78:1057–1060.
   PubMed Web of Science ®Google Scholar
• Kazenwadel J, Secker GA, Betterman KL, et al. In vitro assays using primary embryonic mouse lymphatic endothelial cells uncover key roles for FGFR1 signalling in lymphangiogenesis. PLoS One. 2012;7:e40497.
   Google Scholar
• Koika V, Varnavas P, Valavani H, et al. Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH). Gene. 2013;516:146–151.
   PubMed Web of Science ®Google Scholar
• Gonçalves C, Bastos M, Pignatelli D, et al. Novel FGFR1 mutations in Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism: evidence for the involvement of an alternatively spliced isoform. Fertil Steril. 2015;104(1261–1267):e1261.
   Google Scholar
• Purushothaman R, Tc C, Maga AM, et al. Facial suture synostosis of newborn Fgfr1(P250R/+) and Fgfr2(S252W/+) mouse models of pfeiffer and apert syndromes. Birth Defects Res A Clin Mol Teratol. 2011;91:603–609.
   PubMed Web of Science ®Google Scholar
• Batley BL, Doherty AM, Hamby JM, et al. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 1998;62:143–150.
   PubMed Web of Science ®Google Scholar
• Skaper SD, Kee WJ, Facci L, et al. The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects. J Neurochem. 2000;75:1520–1527.
   PubMed Web of Science ®Google Scholar
• Machida S, Saga Y, Takei Y, et al. Combination therapy of tyrosine kinase receptor inhibitor TSU-68 (SU6668) and paclitaxel inhibits subcutaneous xenografts of endometrial cancer. Mol Med Rep. 2008;1:843–846.
   PubMed Web of Science ®Google Scholar
• Ayers M, Fargnoli J, Lewin A, et al. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res. 2007;67:6899–6906.
   PubMed Web of Science ®Google Scholar
• Cai ZW, Zhang Y, Borzilleri RM, et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem. 2008;51:1976–1980.
   PubMed Web of Science ®Google Scholar
• Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res. 2008;14:6146–6153.
   PubMed Web of Science ®Google Scholar
• Laird AD, Christensen JG, Li G, et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. Faseb J. 2002;16:681–690.
   PubMed Web of Science ®Google Scholar
• Zhen Y, Sorensen V, Jin Y, et al. Indirubin-3ʹ-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. Oncogene. 2007;26:6372–6385.
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005;105:2941–2948.
   PubMed Web of Science ®Google Scholar
• Fletcher GC, Brokx RD, Denny TA, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011;10:126–137.
   PubMed Web of Science ®Google Scholar
• Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007;110:3729–3734.
   PubMed Web of Science ®Google Scholar
• Bhide RS, Cai ZW, Zhang YZ, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem. 2006;49:2143–2146.
   PubMed Web of Science ®Google Scholar
• Dempke WC, Zippel R. Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor. Anticancer Res. 2010;30:4477–4483.
   PubMed Web of Science ®Google Scholar
• Shiang CY, Qi Y, Wang B, et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat. 2010;123:747–755.
   PubMed Web of Science ®Google Scholar
• Patel RR, Sengupta S, Kim HR, et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer. 2010;46:1537–1553.
   PubMed Web of Science ®Google Scholar
• Nakamura I, Zakharia K, Banini BA, et al. Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PLoS One. 2014;9:e92273.
   Google Scholar
• Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology. 2014;60:1697–1707.
   PubMed Web of Science ®Google Scholar
• Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72:2045–2056.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen Y, Tong L, et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J Cell Mol Med. 2012;16:2321–2330.
   PubMed Web of Science ®Google Scholar
• Bello E, Colella G, Scarlato V, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011;71:1396–1405.
   PubMed Web of Science ®Google Scholar
• Kammasud N, Boonyarat C, Tsunoda S, et al. Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2007;17:4812–4818.
   PubMed Web of Science ®Google Scholar
• Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54:7066–7083.
   PubMed Web of Science ®Google Scholar
• Fan J, Dai Y, Shao J, et al. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors. Bioorg Med Chem Lett. 2016;26:2594–2599.
   PubMed Web of Science ®Google Scholar
• Liu J, Peng X, Dai Y, et al. Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold. Org Biomol Chem. 2015;13:7643–7654.
   PubMed Web of Science ®Google Scholar
• Zhao G, Li WY, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011;10:2200–2210.
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Akiyama N, Tsukaguchi T, et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014;13:2547–2558.
   PubMed Web of Science ®Google Scholar
• Gryshchenko AA, Bdzhola VG, Balanda AO, et al. Design, synthesis and biological evaluation of N-phenylthieno[2,3-d]pyrimidin-4-amines as inhibitors of FGFR1. Bioorg Med Chem. 2015;23:2287–2293.
   PubMed Web of Science ®Google Scholar
• Gryshchenko AA, Tarnavskiy SS, Levchenko KV, et al. Design, synthesis and biological evaluation of 5-amino-4-(1H-benzoimidazol-2-yl)-phenyl-1,2-dihydro-pyrrol-3-ones as inhibitors of protein kinase FGFR1. Bioorg Med Chem. 2016;24:2053–2059.
   PubMed Web of Science ®Google Scholar
• Ye F, Chen L, Hu L, et al. Design, synthesis and preliminary biological evaluation of C-8 substituted guanine derivatives as small molecular inhibitors of FGFRs. Bioorg Med Chem Lett. 2015;25:1556–1560.
   PubMed Web of Science ®Google Scholar
• Yan W, Wang X, Dai Y, et al. Discovery of 3-(5ʹ-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazo les as potent fibroblast growth factor receptor inhibitors: design, synthesis, and biological evaluation. J Med Chem. 2016;59:6690–6708.
   PubMed Web of Science ®Google Scholar
• Watanabe Miyano S, Yamamoto Y, Kodama K, et al. A novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models. Mol Cancer Ther. 2016 Nov;15(11):2630–2639.
   Google Scholar
• Tsimafeyeu I, Zaveleva E, Stepanova E, et al. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Invest New Drugs. 2013;31:1436–1443.
   PubMed Web of Science ®Google Scholar
• Samms RJ, Lewis JE, Lory A, et al. Antibody-Mediated inhibition of the FGFR1c isoform induces a catabolic lean state in Siberian hamsters. Curr Biol. 2015;25:2997–3003.
   PubMed Web of Science ®Google Scholar
• Lelliott CJ, Ahnmark A, Admyre T, et al. Monoclonal antibody targeting of fibroblast growth factor receptor 1c ameliorates obesity and glucose intolerance via central mechanisms. PLoS One. 2014;9:e112109.
   PubMed Web of Science ®Google Scholar
• Zhao WM, Wang L, Park H, et al. Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res. 2010;16:5750–5758.
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008;27:85–97.
   PubMed Web of Science ®Google Scholar
• Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest. 2009;119:1216–1229.
   PubMed Web of Science ®Google Scholar
• Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111–137.
   PubMed Web of Science ®Google Scholar
• Herbst RS. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer. 2006;8(Suppl 1):S23–S30.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807–815.
   PubMed Web of Science ®Google Scholar
• Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009;10:28–35.
   PubMed Web of Science ®Google Scholar
• Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat. 2008;11:219–230.
   PubMed Web of Science ®Google Scholar